Corvus Pharmaceuticals CRVS Increase (Decrease) in Other Current Assets
Increase (Decrease) in Other Current Assets at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherCurrentAssets.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's increase (decrease) in other current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's increase (decrease) in other current assets?
- Corvus Pharmaceuticals (CRVS) reported increase (decrease) in other current assets of $865K in Q1 2026.
- How has Corvus Pharmaceuticals's increase (decrease) in other current assets changed year-over-year?
- Corvus Pharmaceuticals's increase (decrease) in other current assets increased by 28933.3% year-over-year, from -$3K to $865K.
- What is the long-term trend for Corvus Pharmaceuticals's increase (decrease) in other current assets?
- Over 2 years (2022 to 2025), Corvus Pharmaceuticals's increase (decrease) in other current assets has grown at a 44.4% compound annual growth rate (CAGR), from -$107K to $223K.